Objective: To collect randomized controlled trial (RCT) literature on the treatment of epilepsy with Ditan Decoction with modifications in recent years, and to use Meta-analysis method based on objective data to demonstrate the fficacy and safety of the treatment.

Methods: Chinese and English databases such as CNKI, VIP, Wanfang data were searched for randomized clinical trials on the treatment of epilepsy with Ditan Decoction. After strict screening the quality was evaluated using the Cochrane evaluation tool, Meta-analysis was conducted using RevMan 5.4 software, and conclusions were drawn.

Results: A preliminary search yielded 115 articles, of which 16 were finally included, totaling 1510 patients with epilepsy enrolled. Meta-analysis results showed that the overall clinical ficacy of Ditan Decoction combined with anti-epileptic drugs [AEDs) in the treatment of epilepsy: RR = 1.23,95% CI; 116-131,Z=7.10,P<0.000 01; seizure frequency: SMD=-2.07,95%CI:- 2.87~- 1.27,Z=5.10,P<0.000 01; quality of life: SMD=1.00, 95%CI; 0.75-1.26,Z=7.66, P<0.00001; lL-6:SMD=-2.28, 95%CI:-2.66~-1.91,Z=11.92,P< 0.000 01; hs-CRP: MD= -0.94,95%CI: -1.29~-0.59,Z= 5.32,P<000 01; MDA: MD= -1.71, 95%CI:-2.59~-0.83,Z= 3.80,P=0.000 1; SOD: MD=23.72,95% Cl:22.86-24.57,Z = 54.32, P<0.000 01; adverse reactions after medication: RR= 0.45, 95%CI 0.30-0.68,Z- 3.87,P= 0.000 1. The above indicators of the research group were superior to those of the control group, and the differences were statistically significant.

Conclusion: Ditan Decoction with modifications combined with AEDs is superior t conventional AEDs treatment for epilepsy, with fewer adverse reactions and high safety. However, due to limitations in the quality and quantity of the included RCT, the relevant conclusions serve only as a reference for the clinical diagnosis and treatment of epilepsy, and more high-quality research is needed to further confirm its efficacy.